

BRYAN TURNER

CV

SCIENTIFIC LEADER AT:

50 YEARS OF HISTONE ACETYLATION

BARCELONA CONFERENCES ON
EPIGENETICS AND CANCER**October, 1st and 2nd, 2014, Barcelona**

Bryan Turner, Professor of Experimental Genetics, School of Cancer Sciences, at [College of Medical and Dental Sciences](#), Institute of Biomedical Research, University of Birmingham, Birmingham, UK

Bryan Turner carried out his PhD work in human biochemical genetics at the Galton Laboratory, University College London. This was followed by five years in Clinical Genetics at Mt Sinai School of Medicine, New York and three in the Division of Immunology at the National Institute for Medical Research, Mill Hill. In 1981 Bryan moved to the University of Birmingham Medical School, where he is now Professor of Experimental Genetics and heads the Chromatin and Gene Expression Group. Shortly after arriving in Birmingham Bryan proposed that acetylation of specific lysines on the histone tails might exert specific functional effects and sought ways to test this hypothesis. To this end he pioneered the production and application of antisera that recognise specifically modified histone isoforms (Turner et al 1992 Cell 69, 375; Turner 1993 Cell 75, 5). The Turner group is now based in the Institute for Biomedical Research (IBR), a five-story research building completed in 2003 and located adjacent to the new Queen Elizabeth Hospital, Birmingham Women's Hospital and the Medical School. Epigenetics is a rapidly developing research theme within the IBR and links groups working with a variety of model organisms, including mouse, zebra fish and Drosophila, all with the ultimate aim of improving understanding and treatment of human disease.

B•DEBATE IS AN INITIATIVE OF:

www.bdebate.org